Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue World Journal of Gastroenterology Année : 2015

Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study

Résumé

AIM: To investigate if correction of hypovitaminosis D before initiation of Peg-interferon-alpha/ribavirin (PegIFN/RBV) therapy could improve the efficacy of PegIFN/RBV in previously null-responder patients with chronic genotype 1 or 4 hepatitis C virus (HCV) infection. METHODS: Genotype 1 or 4 HCV-infected patients with null response to previous PegIFN/RBV treatment and with hypovitaminosis D (< 30 ng/mL) prospectively received cholecalciferol 100000 IU per week for 4 wk [from week-4 (W-4) to W0], followed by 100000 IU Terrier B et al. Vitamin D plus peg-IFN/ribavirin in chronic HCV infection 5648 May 14, 2015|Volume 21|Issue 18| WJG|www.wjgnet.com per month in combination with PegIFN/RBV for 12 mo (from W0 to W48). The primary outcome was the rate of early virological response defined by an HCV RNA < 12 IU/mL after 12 wk PegIFN/RBV treatment. RESULTS: A total of 32 patients were included, 19 (59%) and 13 (41%) patients were HCV genotype 1 and 4, respectively. The median baseline vitamin D level was 15 ng/mL (range: 7-28). In modified intention-to-treat analysis, 29 patients who received at least one dose of PegIFN/RBV were included in the analysis. All patients except one normalized their vitamin D serum levels. The rate of early virologic response was 0/29 (0%). The rate of HCV RNA < 12 IU/mL after 24 wk of PegIFN/RBV was 1/27 (4%). The safety profile was favorable. CONCLUSION: Addition of vitamin D to PegIFN/RBV does not improve the rate of early virologic response in previously null-responders with chronic genotype 1 or 4 HCV infection. Core tip: Vitamin D deficiency is commonly found in patients with chronic hepatitis C virus (HCV) infection and was shown to correlate with sustained virologic response rates to peg-interferon-alpha/ribavirin (PegIFN/RBV) therapy. The addition of vitamin D to PegIFN/RBV was well tolerated but did not improve the rate of early virologic response in previously null-responder patients with chronic genotype 1 or 4 HCV infection.
Fichier principal
Vignette du fichier
5647.pdf (1.08 Mo) Télécharger le fichier
Origine : Publication financée par une institution
Loading...

Dates et versions

hal-01222552 , version 1 (02-11-2015)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Benjamin Terrier, Nathanael Lapidus, Stanislas Pol, Lawrence Serfaty, Vlad Ratziu, et al.. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study. World Journal of Gastroenterology, 2015, 21 (18), pp.5647-5653. ⟨10.3748/wjg.v21.i18.5647⟩. ⟨hal-01222552⟩
288 Consultations
107 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More